Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease

Neurology

Volumn 61, Issue 11 SUPPL. 6, 2003, Pages

  Weiss, Scott M ^a   Benwell, K ^a   Cliffe, I A ^a   Gillespie, R J ^a   Knight, A R ^a   Lerpiniere, J ^a   Misra, A ^a   Pratt, R M ^a   Revell, D ^a   Upton, R ^a   Dourish, C T ^a  

^a Vernalis PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIMALARIAL AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; ISTRADEFYLLINE; MEFLOQUINE; THIENO[3,2 D]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VER 6623; VER 6947; VER 7835;

ARTICLE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; LOCOMOTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 10744233114     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000095581.20961.7d     Document Type: Article

References (33)

1. Abbracchio MP, Cattabeni F. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. Ann NY Acad Sci 1999;890:79-92.
2. Fredholm BB, Abbracchio MP, Burnstock G, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 1994;46:143-156.
3. Klotz KN, Hessling J, Hegler J, et al. Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 1998;357:1-9.
4. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 1997;18:338-344.
5. 3H]CGS 21680. Eur J Pharmacol 1989;168:243-246.
6. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
7. Hubble JP, Hauser R. A novel adenosine antagonist (KW-6002) as a treatment for advanced Parkinson's disease with motor complications. Neurology 2002;58:A162.
8. 2A antagonist treatment of Parkinson's disease. Neurology 2002;58:A467.
9. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 1996;313:525-528.
10. Palmer KJ, Holliday SM, Brogden RN. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993;45:430-475.
11. Pous E, Gascon J, Obach J, Corachan M. Mefloquine-induced grand mal seizure during malaria chemoprophylaxis in a non-epileptic subject. Trans R Soc Trop Med Hyg 1995;89:434.
12. Ruff TA, Sherwen SJ, Donnan GA. Seizure associated with mefloquine for malaria prophylaxis. Med J Aust 1994;161:453.
13. van Riemsdijk MM, van der Klauw MM, van Heest JA, et al. Neuropsychiatric effects of antimalarials. Eur J Clin Pharmacol 1997;52:1-6.
14. Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991;45:86-91.
15. Baudry S, Pham YT, Baune B, et al. Stereoselective passage of mefloquine through the blood-brain barrier in the rat. J Pharm Pharmacol 1997;49:1086-1090.
16. Basco LK, Gillotin C, Gimenez F, Farinotti R, Le Bras J. In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum. Br J Clin Pharmacol 1992;33:517-520.
17. Pham YT, Nosten F, Farinotti R, White NJ, Gimenez F. Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol Ther 1999;37:58-61.
18. 2C receptors in CHO-K1 cells. Br J Pharmacol 1999;128:13-20.
19. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000;289:739-745.
20. Gillespie RJ, Lerpiniere J, Gaur S, Adams DR, Knutsen LJS, Ward SE. Preparation of 4-quinolinemethanol Derivatives as Purine Receptor Antagonists. PCT Int. Appl. WO 0013681. Guildford, UK: Cerebrus Pharmaceuticals Limited, 2000:1-76.
21. Gillespie RJ, Lerpiniere J, Giles PR, Adams DR, Knutsen LJS, Cliffe IA. Preparation of 4-quinolinemethanol Derivatives as Purine Receptor Antagonists. (II). PCT Int. Appl. WO 0013682. Guildford, UK: Cerebrus Pharmaceuticals Limited, 2000:1-73.
22. 2A-receptor Antagonists. PCT Int. Appl. WO 0102409. Wokingham, UK: Vernalis Research Limited, 2001:1-88.
23. Gillespie RJ, Lerpiniere J, Dawson CE, Gaur S, Pratt RM. Preparation of thieno[3,2-d]pyrimidines and furano[3,2-d]pyrimidines as Purinergic Receptor Antagonists. PCT Int. Appl. WO 0255524. Wokingham, UK: Vernalis Research Limited, 2002:1-91.
24. Gillespie RJ, Lerpiniere J, Dawson CE, et al. Preparation of Purine Derivatives as Purinergic Receptor Antagonists. PCT Int. Appl. WO 0255521. Wokingham, UK: Vernalis Research Limited, 2002:1-111.
25. 1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1987;336:204-210.
26. 2 receptors in rat brain. J Pharmacol Exp Ther 1989;251:888-893.
27. 2B adenosine receptors. Drug Des Discov 1999;16:217-226.
28. 3 adenosine receptor. Mol Pharmacol 1994;45:978-982.
29. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
30. Bezard E, Imbert C, Gross CE. Experimental models of Parkinson's disease: from the static to the dynamic. Rev Neurosci 1998;9:71-90.
31. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) 1999;147:90-95.
32. 2 receptors modulate haloperidol-induced catalepsy in rats. Eur J Pharmacol 1997;328:135-141.
33. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970;24:485-493.